GLUE

Monte Rosa Therapeutics, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Janku FilipChief Medical Officer
$240k11.8k shares
SellJun 23, 2026
$20.22
$19.17
Versant Venture Capital VI, L.P.10 Percent Owner
$57k9.3k shares
SellSep 13, 2024
$6.16
--
Versant Venture Capital VI, L.P.10 Percent Owner
$96k16k shares
SellSep 12, 2024
$6.00
--
Versant Venture Capital VI, L.P.10 Percent Owner
$3.3M541.9k shares
SellSep 11, 2024
$6.00
--
Versant Venture Capital VI, L.P.10 Percent Owner
$7.4M1.1M shares
SellSep 20, 2024
$6.53
--
Versant Venture Capital VI, L.P.10 Percent Owner
$147k15.6k shares
SellOct 29, 2024
$9.41
--

News

seekingalpha.comMonte Rosa: Initiating Coverage With A Buy On Degrader Platform Potentialseekingalpha.comJun 11globenewswire.comMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 2globenewswire.comMonte Rosa Therapeutics to Participate in Upcoming Investor Conferencesglobenewswire.comMay 20zacks.comMonte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimateszacks.comMay 7globenewswire.comMonte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updatesglobenewswire.comMay 7